Department of Public Health, Aix-Marseille University, Marseille, France.
Department of Public Health, Aix-Marseille University, Marseille, France.
Drug Discov Today. 2021 Oct;26(10):2269-2281. doi: 10.1016/j.drudis.2021.04.020. Epub 2021 Apr 21.
Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shifted their priorities to COVID-19-related issues, the challenges in market authorisation, and price and reimbursement of CGTs were amplified. Nevertheless, it is encouraging to see that some CGT developers are adapting their efforts toward the development of promising COVID-19-related therapeutics and vaccines. Manufacturing resilience, digitalisation, telemedicine, value-based pricing, and innovative payment mechanisms will be increasingly harnessed to ensure that market access of CGTs is not severely disrupted.
新型冠状病毒（COVID-19）对细胞和基因治疗（CGT）行业造成了重大干扰，该行业在材料供应、制造和物流方面历来面临着巨大的复杂性。随着决策者将重点转移到与 COVID-19 相关的问题上，CGT 的市场授权、定价和报销方面的挑战被放大了。尽管如此，令人鼓舞的是，一些 CGT 开发商正在调整其努力，致力于开发有前途的 COVID-19 相关疗法和疫苗。制造弹性、数字化、远程医疗、基于价值的定价和创新的支付机制将被越来越多地利用，以确保 CGT 的市场准入不会受到严重干扰。
